- Home
- LGND vs IDYA Comparison
LGND vs IDYA Comparison
Compare LGND & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGND
- IDYA
- Stock Information
- Founded
- LGND 1987
- IDYA 2015
- Country
- LGND United States
- IDYA United States
- Employees
- LGND N/A
- IDYA N/A
- Industry
- LGND Biotechnology: Pharmaceutical Preparations
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- LGND Health Care
- IDYA Health Care
- Exchange
- LGND Nasdaq
- IDYA Nasdaq
- Market Cap
- LGND 2.3B
- IDYA 2.2B
- IPO Year
- LGND 1992
- IDYA 2019
- Fundamental
- Price
- LGND $111.89
- IDYA $22.18
- Analyst Decision
- LGND Strong Buy
- IDYA Strong Buy
- Analyst Count
- LGND 6
- IDYA 13
- Target Price
- LGND $145.00
- IDYA $53.67
- AVG Volume (30 Days)
- LGND 124.3K
- IDYA 890.0K
- Earning Date
- LGND 02-25-2025
- IDYA 02-18-2025
- Dividend Yield
- LGND N/A
- IDYA N/A
- EPS Growth
- LGND 160.46
- IDYA N/A
- EPS
- LGND 2.47
- IDYA N/A
- Revenue
- LGND $152,422,000.00
- IDYA $3,922,000.00
- Revenue This Year
- LGND $26.86
- IDYA N/A
- Revenue Next Year
- LGND $14.95
- IDYA $251.89
- P/E Ratio
- LGND $45.27
- IDYA N/A
- Revenue Growth
- LGND N/A
- IDYA N/A
- 52 Week Low
- LGND $67.72
- IDYA $22.10
- 52 Week High
- LGND $129.90
- IDYA $47.74
- Technical
- Relative Strength Index (RSI)
- LGND 50.22
- IDYA 31.90
- Support Level
- LGND $102.79
- IDYA $22.17
- Resistance Level
- LGND $112.61
- IDYA $24.06
- Average True Range (ATR)
- LGND 4.01
- IDYA 1.06
- MACD
- LGND 0.39
- IDYA -0.22
- Stochastic Oscillator
- LGND 87.67
- IDYA 1.84
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.